ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Atara Biotherapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$8.96−0.22 (-2.40%)

Close on Oct 19, 2026

Market cap: $134.70M
P/E (TTM): 3.5
Dividend yield: –

Atara Biotherapeutics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31
Cash & Equivalents	8.48	25	26	93	107	202	76	62	81	48	24	22	52	4.21
Short-Term Investments	0	17	26	150	265	300	185	249	87	208	297	82	–	–
Cash & Short-Term Investments	8.50	43	52	243	372	502	261	311	167	256	321	104	52	4.21
Receivables	1.25	1.48	34	40	0.99	1.25	0	–	–	–	–	–	–	–
Inventory	0	11	9.71	1.59	0	–	–	–	–	–	–	–	–	–
Prepaid Expenses & Other	–	–	–	–	12	21	14	12	5.90	4.68	3.92	1.91	0.19	–
Other Current Assets	2.48	10	6.18	10	12	–	–	–	–	–	–	–	–	–
Total Current Assets	12	65	102	295	385	523	273	321	172	261	325	106	52	–
Property, Plant & Equipment	0.07	1.29	3.86	6.30	54	51	54	69	44	3.26	0.27	0.05	0.01	–
Gross Property, Plant & Equipment	0.29	19	20	19	83	70	66	74	45	3.65	–	–	–	–
Accumulated Depreciation	-0.21	-17	-16	-12	-29	-20	-12	-5.08	-1.35	-0.39	–	–	–	–
Operating Lease Right-of-Use Assets	7.06	40	55	68	26	12	14	14	–	–	–	–	–	–
Other Long-Term Assets	0.89	3.10	4.84	7.02	2.37	0.83	0.57	0.57	0.26	0.10	0.11	0.05	0.01	–
Total Assets	20	109	166	376	468	588	343	392	218	264	325	106	52	–
Accounts Payable	0.13	4.37	3.68	6.87	17	7.12	7.96	3.72	15	2.78	1.45	0.44	0.61	–
Accrued Expenses	1.80	6.03	19	7.44	5.96	3.02	3.90	5.63	–	–	–	–	–	–
Current Portion of Leases	1.03	13	11	13	2.58	1.73	1.31	0	–	–	–	–	–	–
Current Income Taxes Payable	–	–	–	–	–	–	–	–	–	–	–	0.00	0.16	–
Deferred Revenue (Current)	–	–	78	–	–	33	–	–	–	–	–	–	–	–
Other Current Liabilities	2.98	20	32	21	9.06	6.06	5.73	6.41	3.27	0.74	–	–	–	–
Total Current Liabilities	15	135	142	79	106	83	37	40	28	9.68	9.71	2.72	1.52	–
Long-Term Leases	9.35	30	46	58	26	13	14	0	–	–	–	–	–	–
Operating Lease Liabilities	10	43	57	71	28	15	15	15	–	–	–	–	–	–
Other Long-Term Liabilities	1.80	3.27	4.63	5.56	1.50	2.04	1.28	13	–	–	–	0.22	0.23	–
Total Liabilities	59	206	265	250	189	126	52	53	40	10	9.88	2.94	1.75	–
Common Stock	0.00	0.00	0	0.01	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00	–
Additional Paid-In Capital	1,983	1,957	1,870	1,822	1,745	1,587	1,109	867	475	431	414	144	2.20	–
Retained Earnings	-2,022	-2,055	-1,969	-1,693	-1,465	-1,125	-818	-527	-297	-177	-98	-41	-13	–
Comprehensive Income & Other	0.00	0.01	-0.20	-2.07	-0.37	0.30	0.22	-0.34	-0.15	-0.18	-0.52	-0.10	–	–
Shareholders' Equity	-39	-97	99	127	280	462	291	339	178	254	315	103	-11	-3.73
Total Equity	-39	-97	99	127	280	462	291	339	178	254	315	103	-11	-3.73
Total Liabilities & Equity	20	109	166	376	468	588	343	392	218	264	325	106	52	–
Shares Outstanding(shares)	7.32	5.86	4.26	3.84	3.67	3.33	2.27	1.84	1.23	1.16	1.14	0.79	0.48	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -229.7%
Net margin: -269.4%
Return on equity, FY2025: -48.1%

Financial strength

Current ratio: 1.98
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 47.0%

Valuation

P/E ratio: 3.5
Price to sales: 21.75
Price to book: –
Dividend yield: –